Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Humanin

HN, S14G-Humanin

Quick Stats
Studies 491
Trials 100
Score 2
2022 pubmed 16 citations

Effect of Humanin G (HNG) on inflammation in age-related macular degeneration (AMD).

Nashine. Sonali S; Cohen. Pinchas P; Wan. Junxiang J; Kenney. M Cristina MC

Key Findings

  • AMD patients have lower circulating humanin levels than healthy controls
  • Humanin G treatment lowered a wide range of inflammatory markers in AMD‑derived retinal cell models
  • The anti‑inflammatory effect points to a possible role for humanin in mitigating mtDNA‑driven inflammation in AMD

Practical Outcomes

  • Humanin supplementation could be explored as a strategy to support retinal health and reduce inflammation, but current evidence is limited to cell studies. Biohackers should wait for human trials before adopting specific dosing protocols, and consider it an experimental adjunct rather than a proven therapy.

Summary

The study found that people with age‑related macular degeneration (AMD) have lower levels of the peptide humanin in their blood, and that adding a lab‑made version called Humanin G to eye‑cell models reduced many inflammation‑related proteins. This suggests humanin might help calm inflammation linked to AMD, but the work was done in cells, not in people.

Abstract

Inflammation plays a crucial role in the etiology and pathogenesis of AMD (Age-related Macular Degeneration). Humanin G (HNG) is a Mitochondrial Derived Peptide (MDP) that is cytoprotective in AMD and can protect against mitochondrial and cellular stress induced by damaged AMD mitochondria. The goal of this study was to test our hypothesis that inflammation-associated marker protein levels are increased in AMD and treatment with HNG leads to reduction in their protein levels. Humanin protein levels were measured in the plasma of AMD patients and normal subjects using ELISA assay. Humanin G was added to AMD and normal (control) cybrids which had identical nuclei from mitochondria-deficient ARPE-19 cells but differed in mitochondrial DNA (mtDNA) content derived from clinically characterized AMD patients and normal (control) subjects. Cell lysates were extracted from untreated and HNG-treated AMD and normal cybrids, and the Luminex XMAP multiplex assay was used to measure the levels of inflammatory proteins. AMD plasma showed reduced Humanin protein levels, but higher protein levels of inflammation markers compared to control plasma samples. In AMD RPE cybrid cells, Humanin G reduced the CD62E/ E-Selectin, CD62P/ P-Selectin, ICAM-1, TNF-α, MIP-1α, IFN-γ, IL-1β, IL-13, and IL-17A protein levels, thereby suggesting that Humanin G may rescue from mtDNA-mediated inflammation in AMD cybrids. In conclusion, we present novel findings that: A) show reduced Humanin protein levels in AMD plasma vs. normal plasma; B) suggest the role of inflammatory markers in AMD pathogenesis, and C) highlight the positive effects of Humanin G in reducing inflammation in AMD.

Study Information

Provider

pubmed

Year

2022

Date

2022-05-16T00:00:00.000Z

DOI

10.18632/aging.204074

Citations

16

References

139